![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 7 of 7. This is the beginning of the thread.
Posted by SLS on June 21, 2014, at 13:53:31
New Compound Could Treat Depression Without Unwanted Side Effects
There may be a new compound to treat depression. Scientists have found that hydroxynoketamine (HNK) may treat symptoms of depression just as effectively and rapidly as ketamine without the unwanted side effects associated with the psychoactive drug.
"The clinical use of ketamine therapy for depression is limited because the drug is administered intravenously and may produce adverse effects such as hallucinations and sedation to the point of anesthesia," said Irving Wainer, one of the researchers, in a news release. "We found that the HNK compound significantly contributes to the anti-depressive effects of ketamine in animals, but doesn't produce the sedation or anesthesia, which makes HNK an attractive alternative as an antidepressant in humans."
HNK is actually one of several different compounds that are produced when ketamine is broken down in the body. The scientists tested HNK in rats to see if it alone could produce the same beneficial effects of ketamine without the unwanted side effects. The researchers gave the rats intravenous doses of ketamine, HNK and another compound produced by ketamine, called norketamine. The researchers analyzed the effect each had on stimulating certain cellular pathways in the rats' brains after 20, 30 and 60 minutes.
So what did they find? It turns out that the compound HNK, like ketamine, produced rapid antidepressant effects. Not only that, but HNK also stimulated neuro-regenerative pathways and initiated regrowth of neurons. It's also 1,000 times more potent than ketamine, doesn't act as an anesthetic agent and can even be taken by mouth.
"HNK's unique properties increase the possibility of the development of a self-administered, daily treatment that works quickly and can be taken at home for a variety of central nervous system diseases," said Wainer in a news release. "This is a very exciting discovery and we hope that the results of this study will enable future investigations into this potentially therapeutic and important compound."
The findings are published in the journal Anesthesiology
Posted by linkadge on June 21, 2014, at 17:07:17
In reply to HNK - Ketamine metabolite as oral antidepressant, posted by SLS on June 21, 2014, at 13:53:31
I wonder if it has the same NMDA effects of ketamine. If not, this might dispute the actual antidepressant target of ketamine.
Linkadge
Posted by MuseMemento on June 22, 2014, at 13:09:41
In reply to Re: HNK - Ketamine metabolite as oral antidepressant, posted by linkadge on June 21, 2014, at 17:07:17
Sounds quite promising. I imagine it's quite a long way from being administered beyond studies to verify its effects. I hope it will be available soon if all this information's consistent.
Posted by Lamdage22 on June 24, 2014, at 12:01:05
In reply to Re: HNK - Ketamine metabolite as oral antidepressant, posted by MuseMemento on June 22, 2014, at 13:09:41
The question for me is: Is it prone to causing or worsening existing psychosis like Ketamine is?
Posted by SLS on June 24, 2014, at 15:53:23
In reply to Re: HNK - Ketamine metabolite as oral antidepressant, posted by Lamdage22 on June 24, 2014, at 12:01:05
> The question for me is: Is it prone to causing or worsening existing psychosis like Ketamine is?
It is impossible to determine from the wording of the article.
The blood levels of some HNK metabolites of ketamine are negatively correlated with psychosis and dissociation, but I don't know which ones have antidepressant properties.
http://www.ncbi.nlm.nih.gov/pubmed/22516044
- Scott
Posted by SLS on June 29, 2014, at 7:55:29
In reply to Re: HNK - Ketamine metabolite as oral antidepressant, posted by linkadge on June 21, 2014, at 17:07:17
Hi Linkadge.
"HNK targets a specific subtype of the nicotinic acetylcholine receptors, the alpha-7 nicotinic receptor, that are located at the nerve junctions, while ketamine targets the N-methy-D- aspartate (NMDA) receptor, which is located throughout the body," Dr. Wainer explained. "The effect of ketamine on the NMDA receptor is the source of the drug's anesthetic activity as well as its unwanted side effects."
- Scott
Posted by Lamdage22 on July 22, 2014, at 13:13:34
In reply to Re: HNK - Ketamine metabolite as oral antidepressant » Lamdage22, posted by SLS on June 24, 2014, at 15:53:23
Im really looking forward to Glyx-13 and corelated treatments.
I wish there was an iPhone app or something that informs you of all pipeline developments.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.